Still 3 more weeks to apply for a PhD with me in cancer evolution! If you want to find out more about the many exciting positions in our department, we're doing a hybrid informal intro tomorrow: chalmers.se/en/current/cal… (Non-Göteborg people can join on Zoom!)

Check out MACHETE protocol is out in Nature Protocols ! 🔪🔪🧬🧬

👑We're so proud to receive a #QAPrize from Her Majesty The Queen today for our #BreastCancer research. Read more about the special event 👇 icr.ac.uk/news-archive/h…

Interested in the interplay between immune system and somatic evolution? Want to step into the big city of London? Please check this opportunity and we can apply to MSCA, a top fellowship!

Great talk by Marnix Jansen at #UCLcancer! Immune selection determines length switches in homopolymers in MMR tumors! Paper in press, keep your eyes open!

¡Vamos Chilenos! 🇨🇱👏 Nicolas Jarry & Alejandro Tabilo make Chilean history together in Rome 💪 Internazionali BNL d'Italia #IBI24

🎉 We're at #ExRdFest today! We're here 12-6pm today and tomorrow – come say hi and find out about #CancerResearch 👋 Find us in the Sir Alexander Fleming Building Imperial College London, in the Creative Science zone. CRUK Convergence Science Centre #PublicEngagement #SciComm

Springer Nature made over $500M in profit in 2022, 27% margin 💰 (outrageous given most publishing costs are covered by public funds) Nature's editors on strike for fair pay Editors are highly skilled professionals who deserve full respect I signed👇 docs.google.com/document/d/1Th…

Does immune evasion matter for driver genes? Our latest work in Genome Biology with Maria Secrier Simon Walker-Samuel Andrea Sottoriva and the fantastic Lucie Gourmet explores how immune evasion impacts the driver landscape during tumor evolution. Check it out: bit.ly/4blmEul

Hypermutator cancers are defined by increased mutation rates. But do mutation rates evolve with time during tumour growth?⏱️ In this work Nature Genetics we show that hypermutator cancers use an unexpected set of genetic gear switches to adapt mutation rates to immune selection.

Does cancer #evolution & intra-tumour heterogeneity predict long-term relapse? We tested the evolutionary paradigm in prostate cancer clinical trials with long follow-up, combining genomics with digital histopathology: nature.com/articles/s4301…

To all my friends in Barcelona! Do not miss this seminar on lineage tracing using methylomics from one of the leading figures of cancer evolution! #CancerEvolution #Cell #Methylation

🚀 Join our Summer (Yes! 🌅) Course at the Universidad de Chile! Master the art of mathematical modeling and data science in tumor evolution. Learn from experts and apply evolutionary theory to real-world cancer data. Register now🌐 bit.ly/4gPybWO

Thrilled to share our discovery of novel long-deletion #signatures—powerful markers for tracking #MMRd #CancerEvolution, even in low-pass (~0.1X) FFPE samples with low tumour content, using our tool #MILO. Check out our preprint for the full story biorxiv.org/content/10.110… (1/8)

📢 Exciting PhD Opportunity! Join evilab.ai to explore immune cell populations in healthy and premalignant breast tissues. Study how BRCA mutations shape the immune landscape and the impact of PARP inhibitors on mutational signatures. Apply>bit.ly/3Y5CN2F